Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study  by Williams, Kerry J. et al.
ORIGINAL ARTICLE
Gemcitabine with carboplatin for advanced biliary tract cancers:
a phase II single institution study
Kerry J. Williams1, Joel Picus1, Kim Trinkhaus2, Chloe C. Fournier1, Rama Suresh1, Joan S. James1 & Benjamin R. Tan1
1Division of Medical Oncology, and 2Department of Biostatistics, Washington University School of Medicine, Saint Louis, MI, USA
Abstracthpb_197 418..426
Background: Only recently has a standard chemotherapy regimen, gemcitabine plus cisplatin, been
established for advanced biliary tract cancers (BTCs) based on a phase III randomized study. The aim of
this phase II single-institution trial was to assess the efficacy and safety of gemcitabine combined with
carboplatin in the first-line treatment of patients with advanced BTCs.
Methods: Patients with histologically proven BTCs, including cholangiocarcinoma or gallbladder and
ampullary carcinomas, were treated with a maximum of nine cycles of intravenous (i.v.) gemcitabine at
1000 mg/m2 over 30 min on days 1 and 8 with i.v. carboplatin dosed at an area-under-the-curve (AUC) of
5 over 60 min on day 1 of a 21-day cycle.
Results: A total of 48 patients with advanced BTCs (35 cholangiocarcinoma, 12 gallbladder and 1
ampullary cancer) were enrolled. A median of four cycles were administered (range: 1–9). The overall
response rate for evaluable patients was 31.1%. Median progression-free survival, overall survival and
6-month survival rates are 7.8 months, 10.6 months and 85.4%, respectively. The most common grade
3–4 toxicities include neutropenia and thrombocytopenia. Grade 3 or 4 non-haematological toxicities
were rare.
Conclusions: Gemcitabine combined with carboplatin has activity against advanced BTCs. Our results
are comparable to other gemcitabine-platinum or gemcitabine-fluoropyrimidine combinations in
advanced BTCs.
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Introduction
Cancers of the biliary tract (BTCs), including intra- and
extra-hepatic cholangiocarcinomas and gallbladder cancers, are
uncommon cancers accounting for approximately 4% of all
gastrointestinal malignancies.1 An estimated 12 000 new cases of
BTCs are diagnosed annually in the United States.2 Surgical
resection remains the only curative treatment for BTCs, however,
only a minority of patients diagnosed with these aggressive
tumours present at an early, localized and surgically resectable
stage. Unfortunately, disease recurrence rates are high despite
curative-intent resection of BTCs. Adjuvant chemotherapy,
with or without radiation, appears to improve outcomes after
resection.3–5
As a result of the lack of early symptoms, most patients
with BTCs present with locally advanced or metastatic disease.
Prognosis is extremely poor for these patients with median
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survival times of less than 1 year.6–11 A small underpowered ran-
domized study suggests that palliative chemotherapy may offer
improvements in quality of life (QOL) and possibly prolong
survival for patients with BTCs compared with best supportive
care (BSC).12 Fluoropyrimydine monotherapy provided modest
response rates of 0–21% in biliary tract tumours.13–16 Gemcitab-
ine, as a single agent, and in combination with other antineoplas-
tics, has been extensively studied in patients with BTCs. Single
agent gemcitabine conferred response rates of 17% to 36%
with median survivals of 6.5–11 months.17–26 Gemcitabine plus a
fluoropyrimidine resulted in response rates of 9.5% to 29%.27–29
Multiple phase II studies combining gemcitabine with a plati-
num compound, either cisplatin or oxaliplatin in patients with
advanced BTCs, resulted in response rate of 21% to 36% and
median survivals of 8.4 months to 15 months.30–34 Moreover, a
pooled analysis of 104 trials with 2810 patients demonstrated a
superior response rate, tumour control rate and a trend towards
improved time to progression for gemcitabine combined with
a platinum compared with fluoropyrimydine-based regimens.35
Recently, the UK ABC-02 randomized Phase III trial demon-
strated superior outcomes for patients treated with gemcitabine
plus cisplatin compared with gemcitabine alone. The authors have
recommended this regimen to be the new standard regimen for
advanced biliary tract cancers.36
Compared with cisplatin or oxaliplatin, carboplatin has a better
non-haematological toxicity profile and tolerability, less require-
ment for pre- and post- chemotherapy hydration and minimal
risk for nephrotoxicity and cumulative peripheral neuropathy.37,38
Gemcitabine plus carboplatin has been evaluated in patients with
other malignancies and found to be tolerable.38–40 We now report
our phase II study combining gemcitabine with carboplatin for
the first-line treatment of patients with advanced BTCs.
Methods
Eligibility
Patients 18 years or older with biopsy-proven advanced, adeno-
carcinoma of the biliary tract and measurable disease were eligible
for this study. Other requirements included the following: Eastern
Cooperative Oncology Group (ECOG) performance status of 0–2,
adequate haematological, renal and hepatic function [absolute
neutrophil count (ANC) 1500/mm3, platelet count 100 000/
mm3 and haemoglobin 9 g/dL, serum creatinine 2 mg/dL,
serum bilirubin 3.0 mg/dL (biliary stents were allowed), serum
transaminases  fivefold the institutional upper limits]. Patients
must not have received any prior chemotherapy for metastatic
disease. Prior adjuvant radiation therapy and chemotherapy
was allowed. At least 3 weeks needed to have elapsed since
any surgery requiring general anaesthesia. Ineligibility criteria
included co-existing severe medical illness and inability to sign
consent. The study was approved by the institutional review board
and informed consent was obtained from all participants prior to
enrolment.
Treatment schedule
Gemcitabine at a dose of 1000 mg/m2 was administered as a
30-min intravenous (i.v.) infusion on day 1 and 8 of a 21-day
cycle. Carboplatin, at an area-under-the-curve (AUC) of 5, was
administered as a 1-h i.v. infusion on day 1 of a 21-day cycle.
Gemcitabine was administered prior to carboplatin on day 1
of each cycle. Patients received a maximum of nine cycles of
therapy. Treatments after the prescribed nine cycles were admin-
istered per treating physician discretion. Dose adjustments
were made as per a study-defined dose modification table
depending on the type and severity of toxicities associated with
study treatment.
Assessment of efficacy and toxicity
At study entry, a full history and a physical examination were
obtained, including vital signs, height and weight. Prior to enrol-
ment, a complete blood count, comprehensive metabolic profile,
b-human chorionic gonadotropin in females, lactic dehydroge-
nase as well as tumour markers including carbohydrate antigen
19-9 (CA19-9) and carcinoembryonic antigen (CEA) were
obtained. Within 28 days of enrolment, baseline tumour measure-
ments were obtained. At the start of each cycle, a history and
physical examination were once again performed, as well as a
complete blood count, comprehensive metabolic profile and
CA19-9 and CEA. Tumour measurements using spiral computed
tomography (CT) scans for response were obtained every three
cycles (every 9 weeks). Responses were classified according to the
Response Evaluation Criteria in Solid Tumors (RECIST).41 Toxic-
ity was graded according to National Cancer Institute Common
Toxicity Criteria (NCI-CTC) version 2.0.
For patients who developed treatment-related toxicities, the
doses of gemcitabine and carboplatin were adjusted according to
protocol-defined parameters. Treatments were delayed if the ANC
was <1500 cells/ml and platelet counts were <100 000 cells/ml or
for any Grade III non-haematological toxicities. Upon recovery,
gemcitabine doses were reduced by 25% and carboplatin dose
was reduced to the calculated AUC dose of four for all subsequent
cycles. Two further dose modifications with another 25% reduc-
tion in the previous gemcitabine dose and reduction of the
carboplatin calculated AUC dose to 3.5 and 3, were allowed. If
any further toxicity requiring dose modification occurred after
these dose reductions, the patient was removed from the study.
The use of granulocyte-colony stimulating growth factors was not
allowed, whereas erythropoietin used for anaemia was used at
the discretion of the treating physician.
Statistical considerations
The primary objective of this phase II trial was to evaluate the
response rate of gemcitabine plus carboplatin in patients with
advanced BTCs. Secondary endpoints include tumour control
rate, time to progression and overall survival. Descriptive statis-
tical methods were used to summarize baseline patient charac-
teristics and adverse event rates. Progression-free survival and
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overall survival rates were calculated using the Kaplan–Meier
methodology.
The two-stage design proposed by Simon42 was used to calculate
sample size to reject a response rate of <20% in favour of a
response rate of 40%. A sample size of 43 patients was determined
to be the number needed to validate the above hypothesis with an
alpha error rate of 0.05 and a power of 0.8. Enrolment of a total of
48 patients was planned in the event of a 10% rate of inevaluable
or ineligible patients.
Results
Patient characteristics
From March 2002 through to September 2006, 49 patients were
enrolled: 35 patients (71%) had cholangiocarcinoma, 12 patients
(25%) had gallbladder cancer, 1 patient (2%) had ampullary
cancer and 1 patient (2%) was found ineligible after our institu-
tional pathological review of outside slides revealed gallbladder
melanoma. The distribution of various baseline patient character-
istics is listed in Table 1. The median age at the time of study entry
was 63 years (range, 31 to 85).
Chemotherapeutic drug administration
A total of 227 cycles of chemotherapy were given among the 48
eligible patients. The median number of treatment cycles given to
patients was 4 (range 1–9).
Sixteen patients (33%) completed the maximum of nine cycles.
Other reasons for discontinuing study treatment include disease
progression (29%), toxicity (33%) and consent withdrawal (4%).
During the course of therapy, 36 (75%) out of 48 patients
required at least one dose modification secondary to haematologi-
cal adverse events. Only one-level dose reduction to gemcitabine
at 750 mg/m2 and carboplatin at AUC of 4 was required in 22
patients (46%), whereas 14 patients (29%) required 2 or more
dose reductions.
Toxicity
All patients treated on study, including the ineligible patient with
melanoma who received one cycle of therapy, were evaluable for
toxicity. There was one possible treatment related death in an
80-year-old female patient with cholangiocarcinoma who com-
pleted three cycles of chemotherapy on protocol with evidence
of stable disease. She subsequently died from non-neutropenic
urosepsis and multi-system organ failure.
The grade and distribution of haematological and non-
haematological toxicities are summarized in Table 2. The most
common haematological toxicities were anaemia (91%), throm-
bocytopenia (67%) and neutropenia (59%). Grade 3 and grade 4
neutropenia and thrombocytopenia occurred in 37% and
20% of patients, respectively. Four patients developed febrile
neutropenia.
The most common non-haematological toxicities observed
were fatigue (61%), transaminitis and elevated alkaline phos-
phatase (41%), nausea (37%), vomiting (28%) and infections
without neutropenia (13%). However, grade 3–4 non-
haematological toxicities were uncommon. (Table 2).
Eleven patients (22%) required hospitalization, most of which
were because of disease progression or reasons unrelated to study
therapy. The most common reasons for admission were cholan-
gitis (3), febrile neutropenia (2), sepsis (2), biliary obstruction,
suicidal ideation and depression, pain control, dehydration,
nausea, ascites, obstructive jaundice, pancreatitis and deep vein
thrombosis. Five patients required more than one hospital
admission (10%).
Table 1 Patient characteristics
Characteristics N (%)
No. of patients enrolled 49
Gender
Male 15 (31%)
Female 34 (69%)
Performance status
ECOG = 0 22 (45%)
ECOG = 1 or 2 27 (55%)
Age (years)
median (range) 63 (31 to 85)
Location of primary tumour (%):
Cholangiocarcinoma 35 (71%)
Gallbladder 12 (25%)
Ampulla of Vater 1 (2%)
Gallbladder melanoma 1 (2%)
Sites of metastasis (%, n = 48)
Locally advanced 8 (17%)
Metastatic 40 (83%)
Previous surgery 19 (39%)
Curative intent 9 (19%)
Cholecystectomy 2
Right hemihepatectomy 3
Right trisegementectomy 2
Whipple 1
Common bile duct resection 1
Palliative 10 (20%)
Bypass surgery 2
Cholecystectomy 6
Whipple with liver resection 1
Omentectomy 1
Prior radiation 6 (12%)
Prior adjuvant chemotherapy: 5 (10%)
5-FU 3 (6%)
gemcitabine 1 (2%)
gemcitabine-taxotere 1 (2%)
Ca19-9
At baseline: median/range 64 (2 to 600 435)
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Efficacy
Among the 48 eligible patients, 3 were inevaluable for response
(discontinuation from study because of an adverse event prior to
first radiological assessment). The overall response rate for the 45
eligible patients with BTCs was 31.1% [95% confidence interval
(CI), 18.2%-46.7%]. Four patients (8.9%) achieved complete
responses and 10 patients (22.2%) had partial responses. Twenty
patients (44.4%) had stable disease. Thus, the overall tumour
control rate (TCR = CR + PR + SD) was noted to be 75.6% (95%
CI, 60.7–87.1%) (Table 3). Eleven patients (24.4%) met the crite-
ria for progressive disease as their best response. A Waterfall plot
of the best response detailing the percentage change from baseline
tumour measurements for each individual patient is represented
in Fig. 1.
Among the 34 evaluable patients with cholangiocarcinoma,
8 patients (23.5%) had a radiological response (1 CR and 7 PR)
and TCR of 73.5%. Six out of the 11 patients (54.5%) with gall-
bladder carcinoma responded to treatment (3 CR and 3 PR) while
another 3 patients (27.3%) had SD (TCR = 81.8%).
Tumour marker responses, as defined by a 50% decrease of
Ca 19-9 from an elevated abnormal baseline value, were observed
in 14 out of 45 (31%) patients.
The median progression-free survival (PFS) for all 48 eligible
patients was 7.8 months (95% CI, 5.8–9.1 months]. Among the 35
patients with cholangiocarcinoma, median PFS was 7.9 months
(95% CI, 5.6–10.5 months] compared with 6.8 months for the 12
patients with gallbladder carcinoma (95% CI, 3.8–9.1 months).
Only one patient remains alive, now 42 months since study
entry. Median overall survival for all 48 eligible patients was 10.6
months (95% CI, 8.8–14.2 months) with observed 6-month and
12-month survival rates of 85.4% (95% CI, 71.8–92.8%) and
43.8% (95% CI, 29.6–57.1%), respectively (Fig. 2). Table 3 sum-
marizes the response to therapy and outcomes for all patients and
among patients with cholangiocarcinoma and gallbladder cancer.
Median survival for patients with gallbladder and cholangiocar-
cinoma are similar at approximately 11 months. Median overall
survival for patients who achieved stable disease was 14.6 months
(95% CI, 10.0–23.0 months], comparable to those who achieved
a partial or complete response whose median survival was 12.1
months (95% CI, 9.0–19.0 months) (Fig. 3). Patients with pro-
gressive disease as their best response had median survival times
of only 7.1 months (95% CI, 5.0–9.6 months).
Among the 48 evaluable patients, 19 patients had prior
surgery. Curative-intent oncological surgery was performed in
Table 2 Maximum severity, per patient, of grade 3 or 4 adverse
events, n = 49
Toxicity Grade 3/
Grade 4
Total
Hematologic
Anaemia 12% 91%
Thrombocytopaenia 20% 67%
Neutropaenia 37% 59%
Lymphopaenia 18% 59%
Non-haematological
Fatigue 6% 61%
Transaminitis (AST/ALT) and increase in
alkaline phosphatase
4% 41%
Nausea 6% 37%
Vomiting 6% 28%
Infection without neutropaenia 4% 13%
Hyperbilirubinaemia 2% 10%
Diarrhoea 4% 8%
Febrile neutropaenia with infection 6% 6%
Febrile neutropaenia without infection 2% 2%
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
Table 3 Response rates, progression-free survival and overall survival for all patients, and by disease site
Total patients Cholangiocarcinoma Gallbladder cancer
Response
N 45a 33 11
Response rate, % 31.1% (95% CI, 18.2–46.7%) 23.5% 54.5%
Stable disease, % 44.4% 50% 27.3%
Tumour-control rate, % 75.6% (95% CI, 60.5–87.1%) 73.5% 81.8%
Survival (ITT)
n, eligible patients 48b 35 12
Progression-free survival, months 7.8 (95% CI, 5.8, 9.1) 7.9 6.8
Overall survival, months 10.6 range = 1–45
(95% CI, 9–15)
10.6
Range = 3–42
11.5
Range = 1–45
6-month survival, % 85.4% (95% CI, 71.8–92.8%) 83.3% 91.7%
12-month survival, % 43.8% (95% CI, 29.6–57.1%) 42.4% 50.0%
aAll evaluable patients including one patient with ampullary cancer.
bAll eligible patients, including one patient with ampullary cancer.
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nine patients who later experienced disease recurrence. Surgery
for 10 patients was palliative in intent, as metastatic disease was
noted during surgery. Median survival for the 19 patients with
prior surgery, whether curative or palliative, was 10.1 months,
slightly worse than those who had no prior surgery (12.1 months).
Discussion
Although biliary tract cancers are relatively uncommon, it is a
devastating disease, usually presenting at advanced stages when
surgery is not a treatment option. Few therapeutic advances have
been made in the recent era with regard to new drug development
for unresectable, locally advanced or metastatic biliary tract
cancers. Multiple agents have been investigated as single or com-
bination therapies in small uncontrolled studies. Historically,
5-fluorouracil (5-FU) has been the most studied agent and has the
longest track record in treating patients with advanced biliary
tract cancers. 5-FU, as single agent therapy, has a response rate of
0–21%.13–16 Other agents, such as mitomycin-C,43 methotrexate,44
etoposide,45 docetaxel,46 and doxorubicin,47 have been used with
mixed results in biliary tract cancers. Only 10–20% of patients
treated with the above chemotherapies showed a response.
Gemcitabine has been evaluated both as a single-agent and in
combination with numerous agents. Most of these studies were
limited as a result of small sample sizes (Table 4). A recent pooled
analysis of 104 clinical trials evaluating gemcitabine plus a plati-
Figure 1 Waterfall Plot. Best objective tumour response for each patient: maximum change in the sum of the longest diameter of measurable
disease from baseline. n = 45 complete/partial responders: >30% decrease; stable disease: <30% decrease to <20% increase; progressive
disease: >20% increase or with new lesions
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Figure 2 Overall and progression-free survival. n = 45
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num regimen in biliary tract cancer35 reported that the pooled RR
and TCR was 22.6% and 57.3%, respectively. Significant correla-
tions of RR and TCR with survival times were found.35
Recently, gemcitabine in combination with cisplatin has been
evaluated in 410 patients with advanced or metastatic cholangio-
carcinoma, gallbladder cancer and ampullary cancers in a large,
randomized phase III clinical trial.36 Gemcitabine plus cisplatin
conferred a significantly superior median overall survival (OS)
compared with those treated with single-agent gemcitabine [11.7
months vs. 8.2 months, P = 0.002, hazard ratio (HR) = 0.68, 95%
CI 0.53–0.86]. The median PFS was also significantly greater with
gemcitabine/cisplatin than gemcitabine alone (8.5 vs. 6.5 months,
P = 0.003, HR = 0.70, 95% CI, 0.56–0.88). Although the response
rate for the combination arm was higher (25.7% vs. 16%), this was
not statistically significant compared with gemcitabine alone. Tox-
icities were similar in both arms, however, neutropenia was found
to be more common in the combination arm. This large phase III
study established a new standard first-line regimen using gemcit-
abine with cisplatin for advanced biliary cancer.
In this single institution phase II clinical trial we demonstrate
that gemcitabine with carboplatin has activity in biliary tract
cancer with an overall response rate of 31.1%, tumour control
rate of 75.5%, median time to progression of 7.8 months and
median overall survival of 10.6 months. The 6-month and 1-year
survival rates were 85.4% and 43.8%, respectively. These results
are comparable to those reported by Valle et al. in their random-
ized study using gemcitabine and cisplatin in a similar popula-
tion of patients with biliary tract tumours.36 These results are
also consistent with other phase II studies using gemcitabine-
based combinations and the pooled analysis data published by
Eckel35 (Table 4).
As there appears to be differences in the clinicopathological
behaviour of the different tumour types comprising these rare
biliary tract malignancies, a subset analysis of outcomes for
patients with cholangiocarcinomas and gallbladder cancers was
done. Although the clinical response rate appears to be higher
among patients with gallbladder cancer, compared with patients
with cholangiocarcinoma, OS for both groups are identical at
approximately 11 months. Patients with stable disease as their best
response still achieved comparable survival times similar to those
who achieved partial or complete responses. Similar to the clinical
experience in pancreatic cancer, significant benefits in outcome
can be observed despite low response rates to chemotherapy.
Unfortunately, most patients progress and die of their malignancy,
including the four patients who achieved a complete radiological
response to treatment. Patients with prior surgery, whether cura-
tive or palliative, appear to have a shorter median survival time
compared with those who never had any prior surgery. However,
this observation needs to be validated in larger studies.
Although severe non-hematological toxicities were uncommon,
haematological toxicities associated with gemcitabine and carbo-
platin, as administered in this protocol, appear higher compared
with the toxicities reported using weekly cisplatin and gemcitab-
ine in the ABC-02 study (Grade 3–4 anemia 12% vs. 6.3%; grade
3–4 thrombocytopenia 20% vs. 8.2% and grade 3–4 neutropenia
37% vs. 22.6%).36 Haematological toxicities associated with this
regimen were also higher than other combinations such as gem-
citabine with capecitabine.29
Gemcitabine in combination with carboplatin has activity
against advanced biliary tract cancers comparable to other
gemcitabine-platinum and gemcitabine fluoropyrimidine combi-
nations. However, haematological toxicities associated with this
combination are significant. This combination should be evalu-
ated among patients who may be intolerant or not suitable for
cisplatin. Further large multicentre randomized trials, preferably
with pharmacogenomic and tissue correlative studies, are neces-
sary to establish more efficacious and tolerable regimens to treat
patients with these rare malignancies.
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Figure 3 Overall survival based on response. n = 45
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